Evidence map›Paper›PMID 35733032›Full record

ArticleJournal of neuro-oncology2023

A prospective cohort study of methotrexate plus idarubicin in newly diagnosed primary CNS lymphoma.

Qing Li, Yan Ma, Zhiguang Lin, Jingjing Ma, Hui Kang, Mengxue Zhang, Huiwen Xu, Bobin Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neuro-oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Qing Li *Department of Hematology, Huashan Hospital, Shanghai, China.
Yan Ma *Department of Hematology, Huashan Hospital, Shanghai, China.
Zhiguang LinDepartment of Hematology, Huashan Hospital, Shanghai, China.
Jingjing MaDepartment of Hematology, Huashan Hospital, Shanghai, China.
Hui KangDepartment of Hematology, Huashan Hospital, Shanghai, China.
Mengxue ZhangDepartment of Hematology, Huashan Hospital, Shanghai, China.
Huiwen XuInstitutes of Biomedical Sciences, Fudan University, Shanghai, China.
Bobin ChenDepartment of Hematology, Huashan Hospital, Shanghai, China. bbchen@fudan.edu.cn.
Huashan Hospital · CNFudan University · CN

Funding

Beijing Medical and Health Foundation No.YWJKJJHKB175BClinical Research Plan of SHDC SHDC 2020CR6005-002Shanghai Shenkang Clinical Innovation Project No.SHDC12020112
6 · The paper itself

Abstract

purposeHigh-dose methotrexate (HD-MTX)-based chemotherapy regimen is the first-line option for primary central nervous system lymphoma (PCNSL). This prospective cohort study aimed to evaluate the efficacy and adverse effects of HD-MTX plus idarubicin (IDA) in patients with newly diagnosed immunocompetent PCNSL.

methodsWe recruited newly diagnosed PCNSL patients from January 2017 to August 2020. Patients were assigned into two groups: HD-MTX monotherapy and HD-MTX plus IDA (HD-MTX/IDA). In the HD-MTX monotherapy group, patients were treated with MTX 8 g/m

resultsWe recruited 61 PCNSL patients, including 36 in the HD-MTX and 25 in the HD-MTX/IDA group. The CR rate was 68% in the HD-MTX/IDA group and 72.22% of patients in the HD-MTX monotherapy group (p = 0.7221), while the overall response rate was 72% vs. 77.78% (p = 0.6063). Median PFS in HD-MTX/IDA group and HD-MTX monotherapy group were 15.6 months and 18.5 months, respectively (p = 0.6374). Median OS was not reached in both groups. There were no significant differences in adverse effects between the two groups.

conclusionsThe combination of IDA with HD-MTX showed no obvious therapeutic advantage over HD-MTX monotherapy in newly diagnosed patients with PCNSL. HD-MTX dose of 8 g/m

Indexed as

Central Nervous System NeoplasmsLymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansIdarubicinMethotrexateProspective StudiesRetrospective StudiesIdarubicinMethotrexateChemotherapyHigh-dose methotrexateIdarubicinPrimary central nervous system lymphomaPrognosis

Identifiers

PMID35733032
OpenAlexW4283257853

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.